You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4429 results
  1. Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Feasibility and design of a novel smartphone app to deliver blood pressure-lowering inspiratory muscle strength training

    SBC: KLEIN BUENDEL, INC.            Topic: NHLBI

    PROJECT SUMMARYHigh blood pressure (BP), particularly high systolic BP (SBP), is the major modifiable risk factor for cardiovascular diseases (CVD) and related conditions. Indeed, over 50% of all adults have above-normal SBP (≥120 mmHg), placing them at increased disease risk. In addition, these adults face ~$2000/year in excess medical expenses compared to their peers with normal BP. Rates of B ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting Myosin to Treat Polycystic Kidney Disease

    SBC: PLUREXA LLC            Topic: 400

    PROJECT SUMMARY The goal of this proposal is to advance a new therapeutic approach targeting myosin for polycystic kidney disease (PKD). PKD is a major life-threatening Mendelian disorder that affects 12,000,000 individuals, representing a market opportunity of ~$1 billion. In PKD, tiny tubules in the kidneys, liver, and other organs gradually expand into fluid-filled cysts, leading to organ failu ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NHLBI

    Summary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Live spike sorting for multichannel and high-channel recordings

    SBC: POPNEURON LLC            Topic: 106

    Project Summary: The goal of this project is to create two prototypes of a novel live spike sorting system which can be used by investigators to spike sort streams of neural data recorded by multi-channel, high channel and ultra-high channel probes. In most in-vivo extracellular recording conditions, an electrode can pick up neural spikes from several nearby neurons resulting in so-called “multi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Dialysate regeneration system based on photo-electrochemical urea oxidation and reactive adsorption to enable portable hemodialysis

    SBC: KULEANA TECHNOLOGY, INC.            Topic: 400

    PROJECT SUMMARY/ ABSTRACT Currently in the US there are over 400,000 kidney patients on dialysis. The primary therapy mode is hemodialysis and is performed in a hospital or private clinic. Current dialysis therapy requires a large device that must be continuously connected to a reverse osmosis (RO) system. A single treatment will require over 150L of AAMI dialysate making portable device unattaina ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Closed-loop laryngeal pacing for voice restoration

    SBC: RIPPLE LLC            Topic: NIDCD

    Project Summary and Abstract The most common neurogenic voice disorder is unilateral vocal fold paralysis (UVFP), which can substantially reduce quality of life. Current available surgical treatments offer only temporary improvement in voice through placement of resorbable materials or involve permanent, invasive alteration of the larynx that incompletely restores voice and often requires revision ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Substance Use Disorder Artificially Intelligent chatbot for screening, assessment and referral: SUD Bot

    SBC: Clinic Chat LLC            Topic: NIDA

    ABSTRACT The opioid epidemic is considered one of the most severe public health crises we are facing in the U.S. and is worsened by use of stimulants such as methamphetamine. The US Preventive Services Task Force (USPSTF) recommends screening for unhealthy drug use accompanied by offers of and referrals to services that include accurate diagnosis, effective treatment and appropriate care of a subs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government